Context Therapeutics (CNTX) Stock: Buy, Sell, or Hold?
CNTX - Context Therapeutics Inc. Common Stock
$0.24
-0.01 (-2.30%)
▼
5d:
-21.84%
30d:
-35.23%
90d:
-62.16%
WAIT
LOW Confidence
Analysis Updated: Oct 19, 2026 12:00 AM ET
Earnings: Nov 04, 2026
14d
Get Alerted When CNTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CNTX is down 21.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CNTX is down 21.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CNTX is currently trading at $0.24, which is considered oversold relative to its 30-day fair value range of $0.28 to $0.37.
Technical Outlook: Technically, CNTX is in a downtrend. Immediate support is located at $0.22, while resistance sits at $0.36.
Market Sentiment: CNTX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.03 (+1591.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CNTX is in a downtrend. Immediate support is located at $0.22, while resistance sits at $0.36.
Market Sentiment: CNTX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.03 (+1591.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.28 -
$0.37
Company Quality Score
40/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1591.5% below Wall St target ($4.03)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.28 -
$0.37
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.22
Resistance Level
$0.36
Current Trend
Downtrend
Technical data as of
Oct 19, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.55
Wall Street Target
$4.03
(+1591.5%)
Share & Embed Analysis
Last updated: October 20, 2026 9:10 AM ET
Data refreshes hourly during market hours. Next update: 10:10 AM
Data refreshes hourly during market hours. Next update: 10:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CNTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
24 analysts |
$258 | 55 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 58 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 54 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 58 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
16 analysts |
$106 | 52 HOLD |
